A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.5c00701 ↗At a glance
Journal article in ACS Applied Materials & Interfaces, 2025. Written by Ling Zhong and 10 co-authors. Institution: College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China. Major MEDLINE topics: Antibodies, Neutralizing, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Vaccines, Virus-Like Particle. Cited 1 times so far (Crossref); 43 references. Funded by: Chongqing Municipal Education Commission, Ministry of Science and Technology of the People's Republic of China, Natural Science Foundation of Chongqing Municipality.
Abstract (original language)
Epstein-Barr Virus (EBV) as the first characterized tumorigenic virus in humans causes heavy disease burdens. An effective vaccine is urgently needed to block EBV infection. Glycoprotein B (gB) is the essential fusogen for EBV infection of all susceptible cell types. We previously demonstrated that neutralizing antibody 3A3 targeting gB effectively blocked EBV infection in a humanized mouse model, indicating that the epitope recognized by 3A3 is the potential immunogen candidate. Hence, we rationally designed a chimeric virus-like particle (cVLP) vaccine based on the hepatitis B core antigen (HBc149) to display gB peptide, αB, recognized by 3A3 (149-αB cVLP). The engineered 149-αB cVLP vaccine self-assembled into spherical particles presenting multiple copies of αB peptide. The 149-αB cVLP vaccine induced much higher antibody titers against αB peptides than gB protein immunization. Importantly, sera antibodies elicited by the 149-αB cVLP vaccine more efficiently blocked EBV infection and membrane fusion of epithelial cells and B cells. Sera from 149-αB cVLP vaccine-immunized rabbits conferred 100% protection against EBV infection in a humanized mouse model. We demonstrated that the 149-αB cVLP vaccine induced potent antigen-specific protective immune responses and shed light on the research of peptide-based vaccines against EBV infection.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China.
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Gua…
- Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.
- Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, PR China.
- State Key Laboratory of Vaccines for Infectious Diseases, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Collab…
ORCID profiles: Mu-Sheng Zeng, Yi-Xin Chen, Xiao Zhang
Funding
- Chongqing Municipal Education Commission
- Ministry of Science and Technology of the People's Republic of China
- Natural Science Foundation of Chongqing Municipality
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
Cite
APA
Zhong, L., Zhang, W., Xiao, R., He, H., Wu, Q., Hong, J., Zeng, M. S., Zhao, Q., Zheng, Q., Chen, Y. X., & Zhang, X. (2025). A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c00701
Vancouver
Zhong L, Zhang W, Xiao R, He H, Wu Q, Hong J, et al. A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c00701
BibTeX
@article{Zhong2025,
author = {Zhong, Ling and Zhang, Wanlin and Xiao, Rui and He, Huiping and Wu, Qian and Hong, Junping and Zeng, Mu-Sheng and Zhao, Qinjian and Zheng, Qingbing and Chen, Yi-Xin and Zhang, Xiao},
title = {A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.5c00701}
}
EUVIMED